secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keros Therapeutics, Inc. (KROS)
CIK:        0001664710
Form:       8-K
Filed at:   2024-08-07T23:59:59+00:00
Accession:  0001664710-24-000067
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Keros Therapeutics reports Q2 2024 net loss of $45.3M; cash runway into 2027
----------------------------------------------------------------------------

- Net loss of $45.3M in Q2 2024, up from $37.5M in Q2 2023 due to increased R&D spend.
- R&D expenses $40.5M (Q2 2024) vs $32.5M (Q2 2023); G&A $10.0M vs $8.8M.
- Cash and equivalents $405.9M as of June 30, 2024, expected to fund operations into 2027.
- Elritercept (KER-050) positive regulatory/data updates; cibotercept (KER-012) Phase 2 PAH enrollment to complete Q4 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1664710/000166471024000067/0001664710-24-000067-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1664710/000166471024000067/kros-20240807.htm
  HTML page:      https://secwatch.observer/filing/0001664710-24-000067

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer